SCD1 enzyme in lipid metabolism sheds light on resistance of certain cancers to treatment
· Medical Xpressedited by Stephanie Baum, reviewed by Robert Egan
Stephanie Baum
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Associate Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
The Cancer Metabolism and Tumor Microenvironment Laboratory at the University of Liège has uncovered a previously unrecognized mechanism that promotes cancer cell survival under therapeutic pressure. Published in MedComm, the study shows how a key enzyme in lipid metabolism, stearoyl-CoA desaturase-1 (SCD1), cooperates with an epigenetic regulator to support tumor growth.
Led by Professor Nor Eddine Sounni, the team investigated how cancer cells adapt to hostile conditions such as hypoxia, nutrient deprivation and exposure to anticancer therapies. These cells reprogram their metabolism, particularly lipid metabolism, to sustain proliferation. While SCD1 has long been associated with aggressive tumor behavior, the precise molecular mechanisms underlying its role in therapy resistance remained poorly understood.
The researchers discovered that SCD1 physically interacts with HDAC2, a major regulator of gene expression and protein activity. This interaction promotes the deacetylation of nucleophosmin-1 (NPM1), a multifunctional protein involved in cellular stress responses and in the regulation of the tumor suppressor p53 pathway.
This newly identified molecular axis, SCD1–HDAC2–NPM1, enhances cancer cell survival under oxidative stress and promotes tumor growth.
"Our work reveals an unexpected link between lipid metabolism and the post-translational regulation of a tumor suppressor-related pathway," explains Sounni. "This discovery provides new insight into how tumor cells adapt to stress and highlights a promising combined therapeutic strategy."
To validate their findings, the researchers used breast and colorectal cancer cell lines as well as mouse models. They demonstrated that inhibition of SCD1 sensitizes cancer cells to HDAC inhibitors, agents already used in oncology. The combination of these approaches produced a synergistic antitumor effect, improving treatment efficacy.
These results pave the way for new therapeutic strategies targeting both lipid metabolism and epigenetic mechanisms. Such approaches could be particularly relevant for treatment-resistant cancers, where therapeutic options remain limited.
More broadly, the study highlights the growing importance of metabolic vulnerabilities in oncology. By disrupting the molecular systems that cancer cells rely on to survive and adapt, combination therapies could enhance treatment response and reduce relapse risk.
The fact that this molecular pathway was observed across multiple cancer types also suggests potential applications beyond a single tumor context.
More information
Coline Wery et al, Stearoyl‐CoA Desaturase‐1 Drives Tumor Growth by Interacting With Histone Deacetylase‐2 and Deacetylating Nucleophosmin‐1, MedComm (2026). DOI: 10.1002/mco2.70809
Key medical concepts
nucleophosmin 1Histone Deacetylase Inhibitors
Clinical categories
Oncology Provided by University de Liege Who's behind this story?
Stephanie Baum
Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: SCD1 enzyme in lipid metabolism sheds light on resistance of certain cancers to treatment (2026, June 22) retrieved 22 June 2026 from https://medicalxpress.com/news/2026-06-scd1-enzyme-lipid-metabolism-resistance.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.